VTv Therapeutics - Stock Price History | VTVT

Historical daily share price chart and data for VTv Therapeutics since 2021 adjusted for splits. The latest closing stock price for VTv Therapeutics as of October 22, 2021 is 1.40.
  • The all-time high VTv Therapeutics stock closing price was 10.89 on July 30, 2015.
  • The VTv Therapeutics 52-week high stock price is 4.75, which is 239.3% above the current share price.
  • The VTv Therapeutics 52-week low stock price is 1.39, which is 0.7% below the current share price.
  • The average VTv Therapeutics stock price for the last 52 weeks is 2.18.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
VTv Therapeutics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 2.2445 1.7900 3.7500 1.4900 1.8600 9.41%
2019 1.7060 2.8200 3.1200 1.2600 1.7000 -35.85%
2018 2.8332 6.0600 7.8300 0.7003 2.6500 -55.91%
2017 5.3741 5.0300 7.7700 3.8300 6.0100 24.43%
2016 5.9323 6.7600 7.3100 4.7300 4.8300 -29.07%
2015 7.7065 10.8900 10.8900 6.1800 6.8100 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.117B $0.006B
vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76